No olvidemos hacer Medicina en la era de la técnica - si somos ajenos a todo lo que hierve debajo de la piel de los pacientes, seremos cualquier cosa, pero no médicos Leed con calma esta entrevista de Julio Flor a Amaia Goirigolzarri 👉🏼blogriojaalavesa.eus/brinda-por-la-…

Hoy Materia Manuel Ansede rescata la figura de Pedro Cuatrecasas, un científico español que brilló en los EEUU: la cromatografía de afinidad y fármacos tan conocidos como aciclovir, gabapentina o atorvastatina son creaciones suyas elpais.com/ciencia/2025-0…

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in Cancer Cell cell.com/cancer-cell/fu…

💙 ¡Gracias, Asociación Iker ‼️ Por vuestro compromiso con la investigación del #LiposarcomaMixoide. La donación se destinará al Grupo de Investigación Traslacional en Sarcomas del #VHIO, liderado por César Serrano García. 👉 linke.to/AIker_VHIO25

🚨New #sarcoma review series! Recently out in Hematology/Oncology Clinics of North America ➡️ a comprehensive number of reviews on specific sarcoma subtypes and timely topics in the field. 🖱️Please click in the link below and get updated! 🔗sciencedirect.com/journal/hemato…

¡Abiertas las inscripciones al #SimposioGEIS2025! 3 de octubre Una cita clave para profesionales implicados en el diagnóstico, tratamiento e investigación de los sarcomas. 👉 Toda la información y formulario de inscripción en nuestra web: grupogeis.org/es/symposiums-…

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets dlvr.it/TLyB5j

I’m happy to share our latest work on tumour necrosis! During my time in the Mikala Egeblad lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13) nature.com/articles/s4158…

Writing is more than words on a page. It’s how we think, feel, and make sense of the world. As AI takes control of that process more and more, it’s important to remember the power of writing as a deeply human act.

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] Ben Westphalen et al. npj Journals Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients

Are drug effects on mRNA & protein levels similar? Below are example dose-response curves of drug-induced changes in protein (blue) and mRNA (pink) abundance. 1/n

🚨 New therapy approved in #sarcoma! EU Medicines Agency has granted the use of 🎯CSFR1 #vimseltinib in patients with #TGCT with funtion deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability ▶️ema.europa.eu/en/medicines/h…

Great news! 🎉 We’ve just published our new scientific article: "EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism" 🧬🧪 One step closer to understanding Ewing sarcoma! nature.com/articles/s4138… IBiS

CTOS is launching a Young Investigators Group for the next generation of sarcomologists. Get involved!

Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry - The Lancet Regional Health – Europe thelancet.com/journals/lanep…

Aquesta setmana hem acomiadat el Dr. Joan Carles. Després de 1️⃣7️⃣ anys treballant al Vall d'Hebron i al VHIO, s’ha jubilat. Gràcies per tots aquests anys de dedicació. Molta sort en aquesta nova etapa ‼️

📢 ¡Simposio para Pacientes! 2 de octubre, Zaragoza . También online Hablamos de diagnóstico molecular y desplazamientos tras el diagnóstico de #sarcomas 🎙️Dra. Ana Sebio y Dr. Javier M. Trufero 🔗 Conexión: us02web.zoom.us/j/85423525565?… #GEIS #Sarcomas #SimposioPacientesGEIS

PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess review of PARP inhibitor approvals emphasizes their efficacy across different cancers based on landmark phase 3 clinical trials. 🔗: acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

DNA copy number variation is strongly buffered at the protein level. The buffering is much stronger than at the RNA level.

Hain nekeza zait zure betiko hutsunea irudikatzea🌹🌹